Cleo Diagnostics (ASX:COV) Shares Outstanding (EOP): 136.86 Mil (As of Dec. 2025)


ASX:COV Cleo Diagnostics Ltd ASX:COV
17 GF Score
Price A$0.50
! 1 Warning Sign
View Full Analysis

What is Cleo Diagnostics Shares Outstanding (EOP)?

Cleo Diagnostics ASX:COV +2.04% 17 Shares Outstanding (EOP) is 136.86 Mil as of Dec. 2025. GuruFocus rates ASX:COV with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Cleo Diagnostics's shares outstanding for the quarter that ended in Dec. 2025 was 136.86 Mil.

Cleo Diagnostics's quarterly shares outstanding increased from Jun. 2025 (128.50 Mil) to Dec. 2025 (136.86 Mil). It means Cleo Diagnostics issued new shares from Jun. 2025 to Dec. 2025 .

Cleo Diagnostics's annual shares outstanding stayed the same from Jun. 2024 (128.50 Mil) to Jun. 2025 (128.50 Mil).


Cleo Diagnostics  (ASX:COV) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Cleo Diagnostics Shares Outstanding (EOP) Related Terms


Cleo Diagnostics Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Cleo Diagnostics's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cleo Diagnostics Shares Outstanding (EOP) Chart

Cleo Diagnostics Annual Data
Trend Jun23 Jun24 Jun25
Shares Outstanding (EOP)
45.00 128.50 128.50

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shares Outstanding (EOP) Get a 7-Day Free Trial 128.50 128.50 128.50 128.50 136.86

ASX:COV vs ABT, SYK, MDT: Shares Outstanding (EOP) Comparison

For the Medical Devices subindustry, Cleo Diagnostics's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cleo Diagnostics Shares Outstanding (EOP) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Shares Outstanding (EOP) falls into.


ASX:COV
17GF Score
Cleo Diagnostics Ltd ASX:COV
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cleo Diagnostics Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 136.86 Mil mean?
Cleo Diagnostics (ASX:COV) has a Shares Outstanding (EOP) of 136.86 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Cleo Diagnostics and its competitors.
Is Cleo Diagnostics' Shares Outstanding (EOP) too high?
Cleo Diagnostics' current Shares Outstanding (EOP) is 136.86 Mil. Overall, Cleo Diagnostics has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Cleo Diagnostics' Shares Outstanding (EOP) compare to ABT and SYK?
Cleo Diagnostics' Shares Outstanding (EOP) of 136.86 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Medical Devices & Instruments company?
A good Shares Outstanding (EOP) depends on the Medical Devices & Instruments industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Cleo Diagnostics and its competitors. Cleo Diagnostics's current Shares Outstanding (EOP) is 136.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleo Diagnostics stock overvalued right now?
Cleo Diagnostics (ASX:COV) has a current Shares Outstanding (EOP) of 136.86 Mil. The current Shares Outstanding (EOP) is 136.86 Mil. Cleo Diagnostics' overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Cleo Diagnostics (ASX:COV), the current Shares Outstanding (EOP) is 136.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cleo Diagnostics Business Description

Address 480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The company's first product to market is intended to be the Triage Test which results to accurately differentiate patients with malignant ovarian cancer from those with benign gynecological conditions. The company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.
17GF Score

Get the complete analysis for ASX:COV

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.50
Price